Are you over 18 and want to see adult content?
More Annotations
A complete backup of www.ilfattoquotidiano.it/2020/02/19/morta-esther-scott-addio-allattrice-di-beverly-hills-90210-e-la-ricerca
Are you over 18 and want to see adult content?
A complete backup of nos.nl/l/2323462
Are you over 18 and want to see adult content?
A complete backup of www.siamsport.co.th/football/atletico/view/175143
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://the-ies.org
Are you over 18 and want to see adult content?
A complete backup of https://pasopacifico.org
Are you over 18 and want to see adult content?
A complete backup of https://kirisute-gomen.com
Are you over 18 and want to see adult content?
A complete backup of https://ereceptionist.co.uk
Are you over 18 and want to see adult content?
A complete backup of https://plkr.org
Are you over 18 and want to see adult content?
A complete backup of https://johnconnollybooks.com
Are you over 18 and want to see adult content?
A complete backup of https://diarioonline.com.br
Are you over 18 and want to see adult content?
A complete backup of https://gsc-europa.eu
Are you over 18 and want to see adult content?
A complete backup of https://roambi.mx
Are you over 18 and want to see adult content?
Text
the
WHAT ARE LAY SUMMARIES Lay summaries make complex information and data from a clinical study understandable for all. We are committed to making information about the latest clinical studies accessible to everyone. This video answers any questions you may have about what lay summaries are, what they include, how we produce them and why they are useful for patients and WELCOME TO ACROSS HEART FAILURE Welcome To ACROSS Heart Failure. ACROSS HF is the global Academy for Cardiovascular Risks, Outcomes and Safety Studies in Heart Failure (HF). Backed by our globally renowned Steering Committee, the ACROSS HF programme provides up-to-date, scientifically robust tools and information to support our multidisciplinary colleagues involved inthe
PREVICOX MANAGER
3D Joints Tool. With the 3D Joints Tool app, the veterinarian can demonstrate to the owner the structure, the movement and the common pathologies of canine joints. This innovative and interactive resource allows the veterinarian to easily explain the diagnosis and the treatment plan to the owner, and to provide the owner with easy tounderstand
ペルサンチン®錠100MG:100錠(10錠×10) PTP供給 …TRANSLATE THIS PAGE ペルサンチン®錠100mg. 100錠 (10錠×10) PTP. 413-741019. 以上. <本件に関するお問い合わせ>. 日本ベーリンガーインゲルハイム株式会社. DIセンター. 電話番号: 0120-189-779. 承り時間: 9:00~18:00 (土・日・祝日・弊社休業日を除く) BOEHRINGER INGELHEIM Boehringer Ingelheim is one of the world's leading research-driven pharmaceutical companies with 130 years of experience. PIPELINE | BOEHRINGER-INGELHEIM.COM Pipeline. Boehringer Ingelheim is clear about its goals. We want to deliver a portfolio of breakthrough medicines that will improve the lives of patients around the word. That starts with innovation. With a pipeline of around 100 clinical and pre-clinical projects, and the potential to deliver up to 15 new medicine approvals by 2025, we BOEHRINGER INGELHEIM CAREERS Locations Our headquarters are in Ingelheim, Germany, and we have 176 affiliates worldwide with around 50,000 employees.; Learning and Development We understand that when you grow, so do we; Meet our colleagues Join us to collaborate, innovate, grow and improve lives!; Benefits and Rewards We offer more for everyone of us. BOEHRINGER INGELHEIM ACQUIRES NORTHERN BIOLOGICS Ingelheim, Germany and Toronto, Canada – 14 May 2020 – Boehringer Ingelheim today announced the acquisition of Northern Biologics Inc., a wholly owned subsidiary of Northern LP. By acquiring this entity, which focuses on therapeutic antibodies targeting the tumor microenvironment, Boehringer Ingelheim is now positioned at the forefront of the stromal biology space - an emerging DISCOVERY RESEARCH POSTDOCTORAL PROGRAM Boehringer Ingelheim’s new postdoctoral program provides talented and ambitious scientists with the opportunity to pursue cutting-edge research with industry-leading colleagues. Participants will explore challenging areas of research and create the starting point for many new therapeutic concepts and technologies, paving the way for the WELCOME TO ACROSS T2D Welcome To ACROSS T2D. ACROSS T2D is the global Academy for Cardiovascular Risks, Outcomes and Safety Studies in Type 2 Diabetes (T2D). Backed by our globally renowned Steering Committee, the ACROSS T2D programme provides up-to-date, scientifically robust tools and information to support our multidisciplinary colleagues involved inthe
WHAT ARE LAY SUMMARIES Lay summaries make complex information and data from a clinical study understandable for all. We are committed to making information about the latest clinical studies accessible to everyone. This video answers any questions you may have about what lay summaries are, what they include, how we produce them and why they are useful for patients and WELCOME TO ACROSS HEART FAILURE Welcome To ACROSS Heart Failure. ACROSS HF is the global Academy for Cardiovascular Risks, Outcomes and Safety Studies in Heart Failure (HF). Backed by our globally renowned Steering Committee, the ACROSS HF programme provides up-to-date, scientifically robust tools and information to support our multidisciplinary colleagues involved inthe
PREVICOX MANAGER
3D Joints Tool. With the 3D Joints Tool app, the veterinarian can demonstrate to the owner the structure, the movement and the common pathologies of canine joints. This innovative and interactive resource allows the veterinarian to easily explain the diagnosis and the treatment plan to the owner, and to provide the owner with easy tounderstand
ペルサンチン®錠100MG:100錠(10錠×10) PTP供給 …TRANSLATE THIS PAGE ペルサンチン®錠100mg. 100錠 (10錠×10) PTP. 413-741019. 以上. <本件に関するお問い合わせ>. 日本ベーリンガーインゲルハイム株式会社. DIセンター. 電話番号: 0120-189-779. 承り時間: 9:00~18:00 (土・日・祝日・弊社休業日を除く) VACCINES | BOEHRINGER-INGELHEIM.COM Vaccines. The Research Process. In Global Innovation, we work across diseases and species to deliver a robust pipeline of safe and effective vaccines for companion animals and livestock. We bring together broad expertise in vaccinology, molecular biology, bioprocess, assay and clinical development. With strong connectionswith academic
PRODUCTS | BOEHRINGER-INGELHEIM.COM Animal Health Products. Everything we do is powered by innovation. Our aim is to provide advanced, preventive animal healthcare and develop smart and effective solutions for those who raise and care for animals. An overview of our animal health products can be viewedbelow.
DIVERSITY & INCLUSION Diversity & Inclusion. We at Boehringer Ingelheim value and respect the differences of our people and nurture a diverse, collaborative and open company culture. For us ‘Diversity is the mix. Inclusion is making the mix work’. Therefore, we foster an inclusive environment which allows diversity to flourish. Valuing the diversity of thought BOEHRINGER INGELHEIM IS A FOUNDING MEMBER OF QUTAC QUTAC. Ingelheim, June 10, 2021 – Today, Boehringer Ingelheim joined the Quantum Technology and Application Consortium (QUTAC) as a founding member. This consortium unites ten of the leading German companies from the fields of chemistry and pharmaceuticals as well as from the insurance business and the automotive industry. POSITIVE PHASE II SCHIZOPHRENIA TRIAL RESULTS Ingelheim, Germany, 14 September 2020 – Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrated BI 425809 has met its primary endpoint.The data showed improvement in cognition in stable adult patients with schizophrenia. 1 Central to many everyday tasks, impairment of cognitive function still constitutes a major burden for MEET THE BD&L TEAM 2019 Welcome to Innovation @ Boehringer Ingelheim. Meet Ioannis Sapountzis, Global Head of Business Development and Licensing, and other members of our BD&L Team. They talk about our approach to partnering and what’s different about working together with Boehringer Ingelheim WEBUY | BOEHRINGER-INGELHEIM.COM weBuy: The New Source to Procure Solution for Boehringer Ingelheim based on SAP Ariba ®.. weBuy, the new Source-to-Procure solution for Boehringer Ingelheim, is a key initiative in order to have an integrated solution for the Source to Procure Process around the globe. weBuy is based on SAP Ariba ® and with this change we will streamline our approach for transacting with our suppliers. VIEW OUR OUR COMMITMENT TO PATIENT SAFETY Patient safety is of utmost importance to Boehringer Ingelheim. To achieve this ultimate goal we actively monitor the safety and the benefit-risk profile of all Boehringer Ingelheim products on an ongoing basis through clinical trials, non-interventional observational studies, and spontaneous reports.PREVICOX MANAGER
3D Joints Tool. With the 3D Joints Tool app, the veterinarian can demonstrate to the owner the structure, the movement and the common pathologies of canine joints. This innovative and interactive resource allows the veterinarian to easily explain the diagnosis and the treatment plan to the owner, and to provide the owner with easy tounderstand
INVOICE MANAGEMENT PLATFORM BI i. When entering reference number we recommend considering adding or removing 'preceding' zeros BOEHRINGER INGELHEIM Boehringer Ingelheim is one of the world's leading research-driven pharmaceutical companies with 130 years of experience. PIPELINE | BOEHRINGER-INGELHEIM.COM Pipeline. Boehringer Ingelheim is clear about its goals. We want to deliver a portfolio of breakthrough medicines that will improve the lives of patients around the word. That starts with innovation. With a pipeline of around 100 clinical and pre-clinical projects, and the potential to deliver up to 15 new medicine approvals by 2025, we BOEHRINGER INGELHEIM CAREERS Locations Our headquarters are in Ingelheim, Germany, and we have 176 affiliates worldwide with around 50,000 employees.; Learning and Development We understand that when you grow, so do we; Meet our colleagues Join us to collaborate, innovate, grow and improve lives!; Benefits and Rewards We offer more for everyone of us. BOEHRINGER INGELHEIM ACQUIRES NORTHERN BIOLOGICS Ingelheim, Germany and Toronto, Canada – 14 May 2020 – Boehringer Ingelheim today announced the acquisition of Northern Biologics Inc., a wholly owned subsidiary of Northern LP. By acquiring this entity, which focuses on therapeutic antibodies targeting the tumor microenvironment, Boehringer Ingelheim is now positioned at the forefront of the stromal biology space - an emerging WELCOME TO ACROSS T2D Welcome To ACROSS T2D. ACROSS T2D is the global Academy for Cardiovascular Risks, Outcomes and Safety Studies in Type 2 Diabetes (T2D). Backed by our globally renowned Steering Committee, the ACROSS T2D programme provides up-to-date, scientifically robust tools and information to support our multidisciplinary colleagues involved inthe
AFTOPOR® / AFTOVAXPUR® / AFTOVAX® / AFTOBOV® OLEOSA Aftopor ® / Aftovaxpur ® / Aftovax ® / Aftobov ® Oleosa / Aftovaxpur ® Doe. FMD vaccines with highly potent and purified antigens (Aftopor ®, Aftovaxpur ®, Aftobov ® Oleosa) have potential marker properties that allow differentiation between infected and vaccinated animals (DIVA) for endemic or emergency situations.. Aftovaxpur ® Doe is suitable for emergency situations only. WELCOME TO ACROSS HEART FAILURE Welcome To ACROSS Heart Failure. ACROSS HF is the global Academy for Cardiovascular Risks, Outcomes and Safety Studies in Heart Failure (HF). Backed by our globally renowned Steering Committee, the ACROSS HF programme provides up-to-date, scientifically robust tools and information to support our multidisciplinary colleagues involved inthe
MEDICAL INSIDER COPD Welcome to the Medical Insider COPD by Boehringer Ingelheim, a podcast offering a breath of fresh air to clinicians treating COPD across the globe. We want to bring you news and insights in COPD right from the source. Thank you for joining us today. The Editorial Board of ‘The Medical Insider COPD Podcast’ is comprised of Professor James Chalmers, the British Lung Foundation Chair ofPREVICOX MANAGER
3D Joints Tool. With the 3D Joints Tool app, the veterinarian can demonstrate to the owner the structure, the movement and the common pathologies of canine joints. This innovative and interactive resource allows the veterinarian to easily explain the diagnosis and the treatment plan to the owner, and to provide the owner with easy tounderstand
ペルサンチン®錠100MG:100錠(10錠×10) PTP供給 …TRANSLATE THIS PAGE ペルサンチン®錠100mg. 100錠 (10錠×10) PTP. 413-741019. 以上. <本件に関するお問い合わせ>. 日本ベーリンガーインゲルハイム株式会社. DIセンター. 電話番号: 0120-189-779. 承り時間: 9:00~18:00 (土・日・祝日・弊社休業日を除く) BOEHRINGER INGELHEIM Boehringer Ingelheim is one of the world's leading research-driven pharmaceutical companies with 130 years of experience. PIPELINE | BOEHRINGER-INGELHEIM.COM Pipeline. Boehringer Ingelheim is clear about its goals. We want to deliver a portfolio of breakthrough medicines that will improve the lives of patients around the word. That starts with innovation. With a pipeline of around 100 clinical and pre-clinical projects, and the potential to deliver up to 15 new medicine approvals by 2025, we BOEHRINGER INGELHEIM CAREERS Locations Our headquarters are in Ingelheim, Germany, and we have 176 affiliates worldwide with around 50,000 employees.; Learning and Development We understand that when you grow, so do we; Meet our colleagues Join us to collaborate, innovate, grow and improve lives!; Benefits and Rewards We offer more for everyone of us. BOEHRINGER INGELHEIM ACQUIRES NORTHERN BIOLOGICS Ingelheim, Germany and Toronto, Canada – 14 May 2020 – Boehringer Ingelheim today announced the acquisition of Northern Biologics Inc., a wholly owned subsidiary of Northern LP. By acquiring this entity, which focuses on therapeutic antibodies targeting the tumor microenvironment, Boehringer Ingelheim is now positioned at the forefront of the stromal biology space - an emerging WELCOME TO ACROSS T2D Welcome To ACROSS T2D. ACROSS T2D is the global Academy for Cardiovascular Risks, Outcomes and Safety Studies in Type 2 Diabetes (T2D). Backed by our globally renowned Steering Committee, the ACROSS T2D programme provides up-to-date, scientifically robust tools and information to support our multidisciplinary colleagues involved inthe
AFTOPOR® / AFTOVAXPUR® / AFTOVAX® / AFTOBOV® OLEOSA Aftopor ® / Aftovaxpur ® / Aftovax ® / Aftobov ® Oleosa / Aftovaxpur ® Doe. FMD vaccines with highly potent and purified antigens (Aftopor ®, Aftovaxpur ®, Aftobov ® Oleosa) have potential marker properties that allow differentiation between infected and vaccinated animals (DIVA) for endemic or emergency situations.. Aftovaxpur ® Doe is suitable for emergency situations only. WELCOME TO ACROSS HEART FAILURE Welcome To ACROSS Heart Failure. ACROSS HF is the global Academy for Cardiovascular Risks, Outcomes and Safety Studies in Heart Failure (HF). Backed by our globally renowned Steering Committee, the ACROSS HF programme provides up-to-date, scientifically robust tools and information to support our multidisciplinary colleagues involved inthe
MEDICAL INSIDER COPD Welcome to the Medical Insider COPD by Boehringer Ingelheim, a podcast offering a breath of fresh air to clinicians treating COPD across the globe. We want to bring you news and insights in COPD right from the source. Thank you for joining us today. The Editorial Board of ‘The Medical Insider COPD Podcast’ is comprised of Professor James Chalmers, the British Lung Foundation Chair ofPREVICOX MANAGER
3D Joints Tool. With the 3D Joints Tool app, the veterinarian can demonstrate to the owner the structure, the movement and the common pathologies of canine joints. This innovative and interactive resource allows the veterinarian to easily explain the diagnosis and the treatment plan to the owner, and to provide the owner with easy tounderstand
ペルサンチン®錠100MG:100錠(10錠×10) PTP供給 …TRANSLATE THIS PAGE ペルサンチン®錠100mg. 100錠 (10錠×10) PTP. 413-741019. 以上. <本件に関するお問い合わせ>. 日本ベーリンガーインゲルハイム株式会社. DIセンター. 電話番号: 0120-189-779. 承り時間: 9:00~18:00 (土・日・祝日・弊社休業日を除く) VACCINES | BOEHRINGER-INGELHEIM.COM Vaccines. The Research Process. In Global Innovation, we work across diseases and species to deliver a robust pipeline of safe and effective vaccines for companion animals and livestock. We bring together broad expertise in vaccinology, molecular biology, bioprocess, assay and clinical development. With strong connectionswith academic
PRODUCTS | BOEHRINGER-INGELHEIM.COM Animal Health Products. Everything we do is powered by innovation. Our aim is to provide advanced, preventive animal healthcare and develop smart and effective solutions for those who raise and care for animals. An overview of our animal health products can be viewedbelow.
BOEHRINGER INGELHEIM IS A FOUNDING MEMBER OF QUTAC 1 day ago · ©QUTAC. Ingelheim, June 10, 2021 – Today, Boehringer Ingelheim joined the Quantum Technology and Application Consortium (QUTAC) as a founding member. This consortium unites ten of the leading German companies from the fields of chemistry and pharmaceuticals as well as from the insurance business and the automotive industry.PARASITICIDES
A key area of expertise within Global Innovation is the discovery and development of new parasiticides for both companion animals and livestock. Parasiticides – such as our Heartgard ®, Frontline ®, NexGard ®, Ivomec ® and LongRange ® lines – have transformed the health of animals across the globe in the past several decades. As a DIVERSITY & INCLUSION Diversity & Inclusion. We at Boehringer Ingelheim value and respect the differences of our people and nurture a diverse, collaborative and open company culture. For us ‘Diversity is the mix. Inclusion is making the mix work’. Therefore, we foster an inclusive environment which allows diversity to flourish. Valuing the diversity of thought POSITIVE PHASE II SCHIZOPHRENIA TRIAL RESULTS Ingelheim, Germany, 14 September 2020 – Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrated BI 425809 has met its primary endpoint.The data showed improvement in cognition in stable adult patients with schizophrenia. 1 Central to many everyday tasks, impairment of cognitive function still constitutes a major burden for MEET THE BD&L TEAM 2019 Welcome to Innovation @ Boehringer Ingelheim. Meet Ioannis Sapountzis, Global Head of Business Development and Licensing, and other members of our BD&L Team. They talk about our approach to partnering and what’s different about working together with Boehringer Ingelheim DISCOVERY RESEARCH POSTDOCTORAL PROGRAM Discovery Research Global Post-Doc Program At-A-Glance. Three research sites: Biberach, Germany; Vienna Austria; Ridgefield, USA; Nine discovery research specialties: Cardiometabolic diseases, Cancer Immunology, Cancer Research, Central Nervous System diseases, Immune Modulation, Immunology & Respiratory diseases, Research Beyond Borders, Biotherapeutics Discovery, New ChemicalOUR PIONEERS
The RESPIMAT® is a true success story. Matthias Hausmann is one of its developers. Boehringer Ingelheim helps to modernize Japan’s work environment. Rolf G. Werner paved the way for the biopharmaceutical business – far beyond Germany. Boehringer Ingelheim has developed a first-in-class treatment for patients with IPF.PREVICOX MANAGER
3D Joints Tool. With the 3D Joints Tool app, the veterinarian can demonstrate to the owner the structure, the movement and the common pathologies of canine joints. This innovative and interactive resource allows the veterinarian to easily explain the diagnosis and the treatment plan to the owner, and to provide the owner with easy tounderstand
BOEHRINGER INGELHEIM Boehringer Ingelheim is one of the world's leading research-driven pharmaceutical companies with 130 years of experience. BOEHRINGER INGELHEIM CAREERSRESEARCH & DEVELOPMENTSTUDENTSDIVERSITY & INCLUSIONWHAT WE DOLEARNING AND DEVELOPMENT Locations Our headquarters are in Ingelheim, Germany, and we have 176 affiliates worldwide with around 50,000 employees.; Learning and Development We understand that when you grow, so do we; Meet our colleagues Join us to collaborate, innovate, grow and improve lives!; Benefits and Rewards We offer more for everyone of us. FINANCIAL HIGHLIGHTS Financial Highlights 2020. Improving the health and quality of life of patients is the goal of the research-driven biopharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases in areas of high unmet medical need. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. PIPELINE | BOEHRINGER-INGELHEIM.COM Pipeline. Boehringer Ingelheim is clear about its goals. We want to deliver a portfolio of breakthrough medicines that will improve the lives of patients around the word. That starts with innovation. With a pipeline of around 100 clinical and pre-clinical projects, and the potential to deliver up to 15 new medicine approvals by 2025, we 2020: POSITIVE BUSINESS MOMENTUM DESPITE COVID-19 IMPACT Solid performance despite COVID-19 pandemic. 2020 was a good year for Boehringer Ingelheim, although the effects of the COVID-19 pandemic were omnipresent. All of its businesses contributed positively to net sales and operating income. The company recorded net sales of 19.57 billion EUR, a 3% increase compared to the previous year. DIABETES INFORMATION FROM BOEHRINGER INGELHEIM About 425 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90 – 95 percent of all cases. This number is projected to increase to 629 million people by 2045 1. Type 2 diabetes is a chronic, progressive condition and long-term complications include stroke, heart attack and cardiovascular death as MEDICAL INSIDER COPD Welcome to the Medical Insider COPD by Boehringer Ingelheim, a podcast offering a breath of fresh air to clinicians treating COPD across the globe. We want to bring you news and insights in COPD right from the source. Thank you for joining us today. The Editorial Board of ‘The Medical Insider COPD Podcast’ is comprised of Professor James Chalmers, the British Lung Foundation Chair of MEDICAL RESEARCH GRANTS & FUNDING External Research Grants. We are interested in the advancement of scientific knowledge regarding Boehringer Ingelheim's products and therapeutic areas of interest. Through support of novel research proposals, investigators or collaborative partners can work togetherwith
ペルサンチン®錠100MG:100錠(10錠×10) PTP供給 …TRANSLATE THIS PAGE ペルサンチン®錠100mg. 100錠 (10錠×10) PTP. 413-741019. 以上. <本件に関するお問い合わせ>. 日本ベーリンガーインゲルハイム株式会社. DIセンター. 電話番号: 0120-189-779. 承り時間: 9:00~18:00 (土・日・祝日・弊社休業日を除く) 2021年4月改訂版 パーキンソン病患者の公的支援制度 に、行政によってさまざまな支援制度が用意されています。例えば、国は発病の機構が明らかで なく、治療方法が確立していない希少な疾病で長期の療養を必要とするものを難病と定義し、その BOEHRINGER INGELHEIM Boehringer Ingelheim is one of the world's leading research-driven pharmaceutical companies with 130 years of experience. BOEHRINGER INGELHEIM CAREERSRESEARCH & DEVELOPMENTSTUDENTSDIVERSITY & INCLUSIONWHAT WE DOLEARNING AND DEVELOPMENT Locations Our headquarters are in Ingelheim, Germany, and we have 176 affiliates worldwide with around 50,000 employees.; Learning and Development We understand that when you grow, so do we; Meet our colleagues Join us to collaborate, innovate, grow and improve lives!; Benefits and Rewards We offer more for everyone of us. FINANCIAL HIGHLIGHTS Financial Highlights 2020. Improving the health and quality of life of patients is the goal of the research-driven biopharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases in areas of high unmet medical need. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. PIPELINE | BOEHRINGER-INGELHEIM.COM Pipeline. Boehringer Ingelheim is clear about its goals. We want to deliver a portfolio of breakthrough medicines that will improve the lives of patients around the word. That starts with innovation. With a pipeline of around 100 clinical and pre-clinical projects, and the potential to deliver up to 15 new medicine approvals by 2025, we 2020: POSITIVE BUSINESS MOMENTUM DESPITE COVID-19 IMPACT Solid performance despite COVID-19 pandemic. 2020 was a good year for Boehringer Ingelheim, although the effects of the COVID-19 pandemic were omnipresent. All of its businesses contributed positively to net sales and operating income. The company recorded net sales of 19.57 billion EUR, a 3% increase compared to the previous year. DIABETES INFORMATION FROM BOEHRINGER INGELHEIM About 425 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90 – 95 percent of all cases. This number is projected to increase to 629 million people by 2045 1. Type 2 diabetes is a chronic, progressive condition and long-term complications include stroke, heart attack and cardiovascular death as MEDICAL INSIDER COPD Welcome to the Medical Insider COPD by Boehringer Ingelheim, a podcast offering a breath of fresh air to clinicians treating COPD across the globe. We want to bring you news and insights in COPD right from the source. Thank you for joining us today. The Editorial Board of ‘The Medical Insider COPD Podcast’ is comprised of Professor James Chalmers, the British Lung Foundation Chair of MEDICAL RESEARCH GRANTS & FUNDING External Research Grants. We are interested in the advancement of scientific knowledge regarding Boehringer Ingelheim's products and therapeutic areas of interest. Through support of novel research proposals, investigators or collaborative partners can work togetherwith
ペルサンチン®錠100MG:100錠(10錠×10) PTP供給 …TRANSLATE THIS PAGE ペルサンチン®錠100mg. 100錠 (10錠×10) PTP. 413-741019. 以上. <本件に関するお問い合わせ>. 日本ベーリンガーインゲルハイム株式会社. DIセンター. 電話番号: 0120-189-779. 承り時間: 9:00~18:00 (土・日・祝日・弊社休業日を除く) 2021年4月改訂版 パーキンソン病患者の公的支援制度 に、行政によってさまざまな支援制度が用意されています。例えば、国は発病の機構が明らかで なく、治療方法が確立していない希少な疾病で長期の療養を必要とするものを難病と定義し、そのUSER ACCOUNT
Accessibility Statement; Terms of Use; Data Privacy; Imprint; © 2010-2021 Boehringer Ingelheim International GmbH. All rightsreserved.
BOEHRINGER INGELHEIM IS A FOUNDING MEMBER OF QUTAC 1 day ago · ©QUTAC. Ingelheim, June 10, 2021 – Today, Boehringer Ingelheim joined the Quantum Technology and Application Consortium (QUTAC) as a founding member. This consortium unites ten of the leading German companies from the fields of chemistry and pharmaceuticals as well as from the insurance business and the automotive industry. STOP OF TREATMENT IN COVID-19 STUDY Ingelheim, Germany, Boehringer Ingelheim today announced that it has decided to discontinue treatment in the Phase II trial of a novel, first-in-class compound for reducing the risk or severity of acute respiratory distress syndrome (ARDS) in patients hospitalized for COVID-19 and requiring non-invasive oxygen support. This decision is based on the recommendation of the trial FINANCIAL HIGHLIGHTS Financial Highlights 2020. Improving the health and quality of life of patients is the goal of the research-driven biopharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases in areas of high unmet medical need. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. DIVERSITY & INCLUSION Diversity & Inclusion. We at Boehringer Ingelheim value and respect the differences of our people and nurture a diverse, collaborative and open company culture. For us ‘Diversity is the mix. Inclusion is making the mix work’. Therefore, we foster an inclusive environment which allows diversity to flourish. Valuing the diversity of thought DIABETES INFORMATION FROM BOEHRINGER INGELHEIM About 425 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90 – 95 percent of all cases. This number is projected to increase to 629 million people by 2045 1. Type 2 diabetes is a chronic, progressive condition and long-term complications include stroke, heart attack and cardiovascular death as POSITIVE PHASE II SCHIZOPHRENIA TRIAL RESULTS Ingelheim, Germany, 14 September 2020 – Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrated BI 425809 has met its primary endpoint.The data showed improvement in cognition in stable adult patients with schizophrenia. 1 Central to many everyday tasks, impairment of cognitive function still constitutes a major burden for BOEHRINGER INGELHEIM ACQUIRES NORTHERN BIOLOGICS Ingelheim, Germany and Toronto, Canada – 14 May 2020 – Boehringer Ingelheim today announced the acquisition of Northern Biologics Inc., a wholly owned subsidiary of Northern LP. By acquiring this entity, which focuses on therapeutic antibodies targeting the tumor microenvironment, Boehringer Ingelheim is now positioned at the forefront of the stromal biology space - an emerging WEBUY | BOEHRINGER-INGELHEIM.COM weBuy: The New Source to Procure Solution for Boehringer Ingelheim based on SAP Ariba ®.. weBuy, the new Source-to-Procure solution for Boehringer Ingelheim, is a key initiative in order to have an integrated solution for the Source to Procure Process around the globe. weBuy is based on SAP Ariba ® and with this change we will streamline our approach for transacting with our suppliers. NEW FOCUS FOR BOEHRINGER INGELHEIM AND LILLY ALLIANCE Ingelheim, Germany, and Indianapolis, US, 4 November 2019 – In a move to better serve people living with and without diabetes, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will modernise their current alliance as of 1 January 2020 and focus its combined expertise and investment on the continued development and commercialisation of Jardiance ® (empagliflozin) in type 2 BOEHRINGER INGELHEIM Boehringer Ingelheim is one of the world's leading research-driven pharmaceutical companies with 130 years of experience. PRODUCTS | BOEHRINGER-INGELHEIM.COM Products Human Pharma. Read more. on Products Human Pharma. Products for Animal Health. Products. PRODUCTS | BOEHRINGER-INGELHEIM.COM Animal Health Products. Everything we do is powered by innovation. Our aim is to provide advanced, preventive animal healthcare and develop smart and effective solutions for those who raise and care for animals. An overview of our animal health products can be viewedbelow.
BOEHRINGER INGELHEIM CAREERS Locations Our headquarters are in Ingelheim, Germany, and we have 176 affiliates worldwide with around 50,000 employees.; Learning and Development We understand that when you grow, so do we; Meet our colleagues Join us to collaborate, innovate, grow and improve lives!; Benefits and Rewards We offer more for everyone of us. COPD TREATMENTS FROM BOEHRINGER INGELHEIM Respiratory. Boehringer Ingelheim has 100 years of heritage in respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. PIPELINE | BOEHRINGER-INGELHEIM.COM Pipeline. Boehringer Ingelheim is clear about its goals. We want to deliver a portfolio of breakthrough medicines that will improve the lives of patients around the word. That starts with innovation. With a pipeline of around 100 clinical and pre-clinical projects, and the potential to deliver up to 15 new medicine approvals by 2025, we DIVERSITY & INCLUSION Diversity & Inclusion. We at Boehringer Ingelheim value and respect the differences of our people and nurture a diverse, collaborative and open company culture. For us ‘Diversity is the mix. Inclusion is making the mix work’. Therefore, we foster an inclusive environment which allows diversity to flourish. Valuing the diversity of thought PREVEXXION® RN MAREK’S DISEASE VACCINES EU PREVEXXION ® RN: the next generation of Marek’s disease vaccines now available in the EU and the UK. PREVEXXION ® RN is the results of unprecedented engineering design in vaccinology which brings optimal safety and efficacy balance; The product’s early Marek’s disease onset of immunity from five days of age provides full protection of broilers, layers and breeders against the most FULL DATA FROM CAROLINA® CARDIOVASCULAR OUTCOME TRIAL Full data from CAROLINA ® outcome trial support long-term cardiovascular safety profile of Trajenta ®. CAROLINA ® demonstrated no increased cardiovascular risk for Trajenta ® (linagliptin) versus glimepiride in the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor ; Adults with diabetes treated with Trajenta ® experienced significantly INVOICE MANAGEMENT PLATFORM BIBOEHRINGER INGELHEIM 2019 REVENUEBOEHRINGER INGELHEIM INVESTORBOEHRINGER INGELHEIM INVESTOR i. When entering reference number we recommend considering adding or removing 'preceding' zeros BOEHRINGER INGELHEIM Boehringer Ingelheim is one of the world's leading research-driven pharmaceutical companies with 130 years of experience. PRODUCTS | BOEHRINGER-INGELHEIM.COM Products Human Pharma. Read more. on Products Human Pharma. Products for Animal Health. Products. PRODUCTS | BOEHRINGER-INGELHEIM.COM Animal Health Products. Everything we do is powered by innovation. Our aim is to provide advanced, preventive animal healthcare and develop smart and effective solutions for those who raise and care for animals. An overview of our animal health products can be viewedbelow.
BOEHRINGER INGELHEIM CAREERS Locations Our headquarters are in Ingelheim, Germany, and we have 176 affiliates worldwide with around 50,000 employees.; Learning and Development We understand that when you grow, so do we; Meet our colleagues Join us to collaborate, innovate, grow and improve lives!; Benefits and Rewards We offer more for everyone of us. COPD TREATMENTS FROM BOEHRINGER INGELHEIM Respiratory. Boehringer Ingelheim has 100 years of heritage in respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. PIPELINE | BOEHRINGER-INGELHEIM.COM Pipeline. Boehringer Ingelheim is clear about its goals. We want to deliver a portfolio of breakthrough medicines that will improve the lives of patients around the word. That starts with innovation. With a pipeline of around 100 clinical and pre-clinical projects, and the potential to deliver up to 15 new medicine approvals by 2025, we DIVERSITY & INCLUSION Diversity & Inclusion. We at Boehringer Ingelheim value and respect the differences of our people and nurture a diverse, collaborative and open company culture. For us ‘Diversity is the mix. Inclusion is making the mix work’. Therefore, we foster an inclusive environment which allows diversity to flourish. Valuing the diversity of thought PREVEXXION® RN MAREK’S DISEASE VACCINES EU PREVEXXION ® RN: the next generation of Marek’s disease vaccines now available in the EU and the UK. PREVEXXION ® RN is the results of unprecedented engineering design in vaccinology which brings optimal safety and efficacy balance; The product’s early Marek’s disease onset of immunity from five days of age provides full protection of broilers, layers and breeders against the most FULL DATA FROM CAROLINA® CARDIOVASCULAR OUTCOME TRIAL Full data from CAROLINA ® outcome trial support long-term cardiovascular safety profile of Trajenta ®. CAROLINA ® demonstrated no increased cardiovascular risk for Trajenta ® (linagliptin) versus glimepiride in the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor ; Adults with diabetes treated with Trajenta ® experienced significantly INVOICE MANAGEMENT PLATFORM BIBOEHRINGER INGELHEIM 2019 REVENUEBOEHRINGER INGELHEIM INVESTORBOEHRINGER INGELHEIM INVESTOR i. When entering reference number we recommend considering adding or removing 'preceding' zeros PRODUCTS | BOEHRINGER-INGELHEIM.COM Animal Health Products. Everything we do is powered by innovation. Our aim is to provide advanced, preventive animal healthcare and develop smart and effective solutions for those who raise and care for animals. An overview of our animal health products can be viewedbelow.
THE CORE OF THE LEITBILD We are independent, family-owned and intend to remain so. We are driven by the desire to serve humankind by improving human and animal health. We feel responsible for our communities and are respectful of our resources. We plan in generations and focus on long termperformance.
DIVERSITY & INCLUSION Diversity & Inclusion. We at Boehringer Ingelheim value and respect the differences of our people and nurture a diverse, collaborative and open company culture. For us ‘Diversity is the mix. Inclusion is making the mix work’. Therefore, we foster an inclusive environment which allows diversity to flourish. Valuing the diversity of thought EVENTS & INITIATIVES World Patient Safety Day. 17 Sep 2020 12:00 AM. Read more. on World Patient Safety Day. World Health Summit October 27-29, 2019. Access toHealthcare.
AAI | BOEHRINGER-INGELHEIM.COM Role model BI Values, by always doing what you say, and saying what you think. Make timely decisions with well-balanced analysis and intuition, particularly in tough situations. Ruthlessly prioritize, then drive execution excellence through discipline and collaboration. Actively give and seek feedback; leverage each other’s strengths to PARTNERING AT BIO DIGITAL 2021 Boehringer Ingelheim at BIO Digital 2021. The innovation power of science and collaboration have never been more compellingly demonstrated than during this last year. RESPIRATORY OVERVIEW Respiratory. Boehringer Ingelheim has 100 years of heritage in respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. DIABETES INFORMATION FROM BOEHRINGER INGELHEIM About 425 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90 – 95 percent of all cases. This number is projected to increase to 629 million people by 2045 1. Type 2 diabetes is a chronic, progressive condition and long-term complications include stroke, heart attack and cardiovascular death asPARASITICIDES
A key area of expertise within Global Innovation is the discovery and development of new parasiticides for both companion animals and livestock. Parasiticides – such as our Heartgard ®, Frontline ®, NexGard ®, Ivomec ® and LongRange ® lines – have transformed the health of animals across the globe in the past several decades. As a PARTNERING INTERESTS IN ANIMAL HEALTH Find out more about our key areas of partnering interest in animalhealth
BOEHRINGER INGELHEIM Boehringer Ingelheim is one of the world's leading research-driven pharmaceutical companies with 130 years of experience. PRODUCTS | BOEHRINGER-INGELHEIM.COM Products | boehringer-ingelheim.com Products PRODUCTS | BOEHRINGER-INGELHEIM.COM Animal Health Products. Everything we do is powered by innovation. Our aim is to provide advanced, preventive animal healthcare and develop smart and effective solutions for BOEHRINGER INGELHEIM CAREERS Locations Our headquarters are in Ingelheim, Germany, and we have 176 affiliates worldwide with around 50,000 employees.; Learning and Development We understand that when you grow, so do we; Meet our colleagues Join us to collaborate, innovate, grow and improve lives!; Benefits and Rewards We offer more for everyone of us. COPD TREATMENTS FROM BOEHRINGER INGELHEIM Respiratory. Boehringer Ingelheim has 100 years of heritage in respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. PIPELINE | BOEHRINGER-INGELHEIM.COM Pipeline. Boehringer Ingelheim is clear about its goals. We want to deliver a portfolio of breakthrough medicines that will improve the lives of patients around the word. DIVERSITY & INCLUSION A successful and family-owned Company. Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies. Learn more about the financial highlights, the corporate vision, the organisation, the Board of Managing Directors and the company's history as well as our engagement for scientific, cultural and environmental purposes. PREVEXXION® RN MAREK’S DISEASE VACCINES EU PREVEXXION ® RN: the next generation of Marek’s disease vaccines now available in the EU and the UK. PREVEXXION ® RN is the results of unprecedented engineering design in vaccinology which brings optimal safety and efficacy balance; The product’s early Marek’s disease onset of immunity from five days of age provides full protection of broilers, layers and breeders against the most FULL DATA FROM CAROLINA® CARDIOVASCULAR OUTCOME TRIAL Full data from CAROLINA ® outcome trial support long-term cardiovascular safety profile of Trajenta ®. CAROLINA ® demonstrated no increased cardiovascular risk for Trajenta ® (linagliptin) versus glimepiride in the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor ; Adults with diabetes treated with Trajenta ® experienced significantly INVOICE MANAGEMENT PLATFORM BIBOEHRINGER INGELHEIM 2019 REVENUEBOEHRINGER INGELHEIM INVESTORBOEHRINGER INGELHEIM INVESTOR i. When entering reference number we recommend considering adding or removing 'preceding' zeros BOEHRINGER INGELHEIM Boehringer Ingelheim is one of the world's leading research-driven pharmaceutical companies with 130 years of experience. PRODUCTS | BOEHRINGER-INGELHEIM.COM Products | boehringer-ingelheim.com Products PRODUCTS | BOEHRINGER-INGELHEIM.COM Animal Health Products. Everything we do is powered by innovation. Our aim is to provide advanced, preventive animal healthcare and develop smart and effective solutions for BOEHRINGER INGELHEIM CAREERS Locations Our headquarters are in Ingelheim, Germany, and we have 176 affiliates worldwide with around 50,000 employees.; Learning and Development We understand that when you grow, so do we; Meet our colleagues Join us to collaborate, innovate, grow and improve lives!; Benefits and Rewards We offer more for everyone of us. COPD TREATMENTS FROM BOEHRINGER INGELHEIM Respiratory. Boehringer Ingelheim has 100 years of heritage in respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. PIPELINE | BOEHRINGER-INGELHEIM.COM Pipeline. Boehringer Ingelheim is clear about its goals. We want to deliver a portfolio of breakthrough medicines that will improve the lives of patients around the word. DIVERSITY & INCLUSION A successful and family-owned Company. Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies. Learn more about the financial highlights, the corporate vision, the organisation, the Board of Managing Directors and the company's history as well as our engagement for scientific, cultural and environmental purposes. PREVEXXION® RN MAREK’S DISEASE VACCINES EU PREVEXXION ® RN: the next generation of Marek’s disease vaccines now available in the EU and the UK. PREVEXXION ® RN is the results of unprecedented engineering design in vaccinology which brings optimal safety and efficacy balance; The product’s early Marek’s disease onset of immunity from five days of age provides full protection of broilers, layers and breeders against the most FULL DATA FROM CAROLINA® CARDIOVASCULAR OUTCOME TRIAL Full data from CAROLINA ® outcome trial support long-term cardiovascular safety profile of Trajenta ®. CAROLINA ® demonstrated no increased cardiovascular risk for Trajenta ® (linagliptin) versus glimepiride in the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor ; Adults with diabetes treated with Trajenta ® experienced significantly INVOICE MANAGEMENT PLATFORM BIBOEHRINGER INGELHEIM 2019 REVENUEBOEHRINGER INGELHEIM INVESTORBOEHRINGER INGELHEIM INVESTOR i. When entering reference number we recommend considering adding or removing 'preceding' zeros PRODUCTS | BOEHRINGER-INGELHEIM.COM Animal Health Products. Everything we do is powered by innovation. Our aim is to provide advanced, preventive animal healthcare and develop smart and effective solutions for THE CORE OF THE LEITBILD We are independent, family-owned and intend to remain so We are driven by the desire to serve humankind by improving human and animal health. RESPIRATORY OVERVIEW Respiratory. Boehringer Ingelheim has 100 years of heritage in respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. AAI | BOEHRINGER-INGELHEIM.COM Intrapreneurship: Together with our customers, we come up with innovative ideas to respond to changing markets. Serve the needs of customers and patients by turning innovative ideas into businessresults.
DIABETES INFORMATION FROM BOEHRINGER INGELHEIM In this podcast series, we hear from a range of experts involved in the care for people living with cardio-renal-metabolic conditions. Throughout the series, we learn how these interconnected systems call for collaboration and an interconnected approach to care. DIVERSITY & INCLUSION A successful and family-owned Company. Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies. Learn more about the financial highlights, the corporate vision, the organisation, the Board of Managing Directors and the company's history as well as our engagement for scientific, cultural and environmental purposes. PARTNERING AT BIO DIGITAL 2021 Boehringer Ingelheim at BIO Digital 2021. The innovation power of science and collaboration have never been more compellingly demonstrated than during this last year. EVENTS & INITIATIVES Find out about our latest science on KRAS and how our Pan-KRAS approaches may address significant unmet need for many cancer patients with limited treatment options.PARASITICIDES
A key area of expertise within Global Innovation is the discovery and development of new parasiticides for both companion animals andlivestock.
PARTNERING INTERESTS IN ANIMAL HEALTH Find out more about our key areas of partnering interest in animalhealth
Skip to main contentInformation for...
Please select
General Use Patients or Carers Health Care Professionals in the US Health Care Professionals outside the US and UK Journalists Jobseekers* Press
* Contact
* Global sites
* About Us
* Corporate Profile
* Our Company
* Vision & Values
* History
* Diversity & Inclusion * Ethics & Compliance* Sustainability
* Making More Health * Access to Healthcare* Compassionate Use
* Press
* Press Releases
* Image Mediapool
* Events & Initiatives* Media Contacts
* COVID-19
* Annual Results
* Global Activities
* Europe
* North America
* South America
* Asia
* Africa
* Australasia
* Products
* Human Pharma
* Animal Health
* Innovation
* Human Pharma
* Pipeline
* Disease Focus
* Research Approach
* Clinical Trial Policy * Boehringer Ingelheim Venture Fund* Partnering
* Funding Opportunities* Animal Health
* R&D for Pharmaceuticals* R&D for Vaccines
* Research Process
* Partnering
* Digital Health
* Perspectives
* Discoveries
* Pioneers
* Partnering
* Connect With Us
* Contact Us
* Where to Meet Us
* Partnering News
* Partnering Newsletter* Working Together
* Overview
* Partnering Interests* How We Work
* What We Do
* What Our Partners Say * Grass Roots Partnering * Programs and Events* Human Pharma
* Cardiovascular
* Stroke Prevention
* Acute Ischaemic Stroke* DVT/PE
* Reversal of Anti-coagulation * Myocardial Infarction* Hypertension
* Oncology
* Lung Cancer
* Respiratory
* Asthma
* COPD
* IPF
* Scleroderma
* Progressive fibrosing ILD * Central Nervous System* Overview
* Metabolic Diseases* Diabetes
* IntroDia
* Immunology
* Overview
* Retinal Health
* Overview
* Animal Health
* About Animal Health Business Unit* Companion Animals
* Pets
* Horses
* Livestock
* Cattle / Ruminants* Swine
* Poultry
* Veterinary Public Health * Our Responsibility* Products
* Featured Stories
* Press Releases
* Biopharma
* Careers
SEARCH FORM
Search
Information for...
Please select
General Use Patients or Carers Health Care Professionals in the US Health Care Professionals outside the US and UK Journalists Jobseekers VALUE THROUGH INNOVATION At Boehringer Ingelheim we are driven by the desire to serve mankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. OUR FOCUS articulates who we are and what we strive for, how we work and what wewant to achieve.
*
Boehringer Ingelheim EmployeesCareers
Working at Boehringer Ingelheim – Being part of a global family As a research-driven pharmaceutical company Boehringer Ingelheim strives to improve health of people and animals everywhere in theworld.
Read moreon
Working at Boehringer Ingelheim – Being part of a global family World Map COVID-19 Global Support Program Boehringer IngelheimCOVID-19
Our Global Support Program Our Global Support Program aims to bring more financial relief, protective materials and medicine donations to healthcare institutions and communities in need around the world.Read moreon
Our Global Support Program*
Pioneers: Break new ground to improve the health of humans andanimals
Our Company
Annual Report 2019
Pioneers: Break new ground to improve the health of humans and animalsRead moreon
Annual Report 2019
Joyce, scleroderma patient from PhiladelphiaVision & Values
More Cherished Moments Innovation in healthcare is about more than just a new approach or technology. We innovate for better health of people and animals.Watch the video on
More Cherished Moments-
Animal Health: A global leader in disease prevention and treatment We create the future of animal wellbeing. Through our innovative and ground-breaking solutions our highly-skilled employees support all our customers who raise and deeply care for their animals.Read more on
Animal Health: A global leader in disease prevention and treatmentInnovation
Pipeline
Our growing, highly innovative pipeline focuses on the research and development of healthcare solutions for people with high unmet medicalneeds.
Read moreon
Pipeline
*
Boehringer Ingelheim EmployeesCareers
Working at Boehringer Ingelheim – Being part of a global family As a research-driven pharmaceutical company Boehringer Ingelheim strives to improve health of people and animals everywhere in theworld.
Read moreon
Working at Boehringer Ingelheim – Being part of a global family World Map COVID-19 Global Support Program Boehringer IngelheimCOVID-19
Our Global Support Program Our Global Support Program aims to bring more financial relief, protective materials and medicine donations to healthcare institutions and communities in need around the world.Read moreon
Our Global Support ProgramPlay Pause Previous
* 1
* 2
* 3
* 4
* 5
* 6
Next
EXPLORE OUR CONTENT
*
*
COVID-19
Our Company
COVID-19
As a company, we consider it our duty to take the best possible care of the protection and health of our employees, our patients and society. Boehringer Ingelheim is engaged at various levels of action to contain and cope with the global spread of COVID-19. Read more on COVID-19*
*
PRESS RELEASE 21 Apr 2020 at 09:00 European Commission approves nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD)Read more on
European Commission approves nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD)*
*
PRESS RELEASE 21 Apr 2020 at 08:15 Boehringer Ingelheim puts patient needs first as reflected in the results of the latest “PatientView” surveyRead more on
Boehringer Ingelheim puts patient needs first as reflected in the results of the latest “PatientView” survey*
*
PRESS RELEASE 21 Apr 2020 at 08:00 Aservo® EquiHaler® wins Red Dot for outstanding design qualityRead more on
Aservo® EquiHaler® wins Red Dot for outstanding design quality*
*
PRESS RELEASE 08 Apr 2020 at 10:00 2019 performance: stronger foundation to absorb global effects ofCOVID-19 pandemic
Read more on
2019 performance: stronger foundation to absorb global effects ofCOVID-19 pandemic
*
*
PRESS RELEASE 08 Apr 2020 at 08:00 Covid Global Support ProgramRead more on
Covid Global Support Program*
*
Pioneers: Break new ground to improve the health of humans andanimals
Our Company
Annual Report 2019
Pioneers: Break new ground to improve the health of humans and animalsRead moreon
Annual Report 2019
*
World Map COVID-19 Global Support Program Boehringer IngelheimCOVID-19
Our Global Support Program Our Global Support Program aims to bring more financial relief, protective materials and medicine donations to healthcare institutions and communities in need around the world.Read moreon
Our Global Support Program* Home:
* Homepage
* About Us
* Corporate Profile
* Careers
* Press
* Global Activities
* Innovation
* Human Pharma
* Animal Health
* Digital Health
* Human Pharma
* Cardiovascular
* Oncology
* Respiratory
* Central Nervous System * Metabolic Diseases* Immunology
* Business Units
* Prescription Medicine* Animal Health
* Biopharma
* Global Activities
* Africa
* Asia
* Australasia
* Europe
* North America
* South America
* tweet
* share
* +1
* Share
* Back To Top
* Youtube
* Terms of Use
* Data Privacy
* Imprint
2010-2020 Boehringer Ingelheim International GmbH. All rightsreserved.
In order to analyse the use and to improve our websites and to inform you about our company on other websites, we would like to use cookies. If you agree, please click “Accept”. If you would like to select individually which cookies we can use, to amend your settings or to receive more detailed information, go to “More information". Cookie Information . Accept More information Through this tool you may choose to activate/deactivate single Technologies used on this website. Cookie Information . Consent to all services*
Essential
Necessary Cookies make a website usable by providing basic functions such as page navigation, language settings and access to secure areas of the website. Since the website cannot function properly without them, you cannot opt-out from this kind of Cookies.More info
*
Session
More info
*
Target Group
More info
*
Optimization
These Cookies help us to make our websites work more efficiently as well as to recognize your device on subsequent visits to get information and statistics on your interaction with our website.More info
*
Adobe Analytics
More info
*
Marketing
These Cookies are used to follow users to other websites to show ads on those sites that are relevant and engaging to the individual user.More info
*
Facebook & Instagram (Facebook Pixel)More info
*
LinkedIn (Insight-Tag)More info
*
Twitter (Conversion Tag)More info
Save settings
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0